Genetic Financial Statements From 2010 to 2024

Stocks USA . 
Stock . Genetic Technologies
GENE Stock  USD 0.77  0.00  0.00%   
Genetic Technologies financial statements provide useful quarterly and yearly information to potential Genetic Technologies investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Genetic Technologies financial statements helps investors assess Genetic Technologies' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Genetic Technologies' valuation are summarized below:
Gross Profit
6 M
Profit Margin
(1.24)
Market Capitalization
3.7 M
Enterprise Value Revenue
0.07
Revenue
9.7 M
There are over one hundred nineteen available fundamental trends for Genetic Technologies, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Genetic Technologies' regular performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. As of November 25, 2024, Market Cap is expected to decline to about 10.2 M. In addition to that, Enterprise Value is expected to decline to about 10 M

Genetic Technologies Total Revenue

5.35 Million

Check Genetic Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genetic Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 508.1 K, Interest Expense of 83.6 K or Total Revenue of 5.3 M, as well as many indicators such as Price To Sales Ratio of 1.33, Dividend Yield of 0.0 or PTB Ratio of 5.56. Genetic financial statements analysis is a perfect complement when working with Genetic Technologies Valuation or Volatility modules.
  
Check out the analysis of Genetic Technologies Correlation against competitors.
For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.

Genetic Technologies Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.9 M6.2 M12.1 M
Very volatile
Other Current Liabilities1 M1.9 M1.2 M
Pretty Stable
Total Current Liabilities4.4 M4.2 M2.3 M
Slightly volatile
Total Stockholder Equity1.7 M1.8 M9.5 M
Very volatile
Property Plant And Equipment Net251.3 K264.5 K441.9 K
Very volatile
Cash969.6 K1 M8 M
Very volatile
Non Current Assets Total2.4 M2.5 M2.5 M
Pretty Stable
Cash And Short Term Investments987.4 K1 M8 M
Very volatile
Net Receivables198.8 K209.3 K653.5 K
Pretty Stable
Common Stock Total Equity89.1 M176.6 M116.3 M
Slightly volatile
Common Stock Shares Outstanding138.8 M132.2 M24.4 M
Slightly volatile
Liabilities And Stockholders Equity5.9 M6.2 M12.1 M
Very volatile
Inventory196.1 K206.5 K451.6 K
Slightly volatile
Other Stockholder Equity7.1 M7.5 M17.8 M
Pretty Stable
Total Liabilities2.4 M4.4 M2.5 M
Slightly volatile
Property Plant And Equipment Gross925.5 K1.5 M717.7 K
Slightly volatile
Total Current Assets3.5 M3.7 M9.6 M
Very volatile
Common Stock98.7 M163.8 M116.7 M
Slightly volatile
Other Current Assets2.4 M2.2 M547.9 K
Slightly volatile
Accounts Payable895.2 K1.5 M717.1 K
Pretty Stable
Short Term Investments17.9 K18.8 K38.6 K
Slightly volatile
Property Plant Equipment759.3 K539.3 K525.2 K
Very volatile
Current Deferred Revenue378.3 K741.6 K284.5 K
Slightly volatile
Non Current Liabilities Total152.6 K160.6 K410.6 K
Pretty Stable
Accumulated Other Comprehensive Income4.5 M4.4 M6 M
Slightly volatile
Other Liabilities128.6 K175.2 K137.8 K
Pretty Stable
Net Tangible Assets10.6 M8.7 M7.8 M
Slightly volatile
Net Invested Capital2.4 M2.5 M9.8 M
Pretty Stable
Capital Stock164.9 M163.8 M137.9 M
Slightly volatile

Genetic Technologies Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization508.1 K534.9 K350.4 K
Slightly volatile
Total Revenue5.3 M7.7 M3.8 M
Very volatile
Other Operating Expenses10 M16.2 M10.6 M
Very volatile
Total Operating Expenses3.7 M3.9 M8.4 M
Slightly volatile
Research Development715.1 K752.8 K2.2 M
Slightly volatile
Selling And Marketing Expenses2.2 M2.6 M2.6 M
Slightly volatile
Selling General Administrative10.7 M10.2 M4.7 M
Pretty Stable
Cost Of Revenue3.9 M3.8 M1.6 M
Slightly volatile
Interest Income74.3 K119.5 K67.8 K
Slightly volatile
Reconciled Depreciation488.7 K534.9 K405.8 K
Slightly volatile

Genetic Technologies Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation508.1 K534.9 K405.7 K
Slightly volatile
Capital Expenditures31.3 K33 K121.5 K
Very volatile
End Period Cash Flow969.6 K1 M8 M
Very volatile
Issuance Of Capital Stock2.4 M2.6 M6 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.331.39723.5 K
Slightly volatile
PTB Ratio5.565.85091.8 K
Slightly volatile
Days Sales Outstanding154101297
Pretty Stable
Book Value Per Share0.01260.01320.2986
Pretty Stable
Average Payables1.1 M1.3 M750.1 K
Slightly volatile
Capex To Depreciation0.05860.06160.3191
Very volatile
PB Ratio5.565.85091.8 K
Slightly volatile
EV To Sales1.311.37833.5 K
Slightly volatile
Inventory Turnover19.1218.21268.5801
Pretty Stable
Days Of Inventory On Hand19.0420.041192.788
Pretty Stable
Payables Turnover2.632.57882.1886
Pretty Stable
Sales General And Administrative To Revenue1.271.33314.7796
Very volatile
Average Inventory251.8 K266.2 K198.5 K
Very volatile
Research And Ddevelopement To Revenue0.09330.09829.5404
Very volatile
Capex To Revenue0.00410.00430.5557
Pretty Stable
Cash Per Share0.00710.00750.3003
Pretty Stable
Days Payables Outstanding278142394
Slightly volatile
Income Quality0.590.80540.8722
Pretty Stable
Intangibles To Total Assets0.320.34670.2964
Pretty Stable
Net Debt To EBITDA0.01340.01271.0905
Very volatile
Current Ratio0.840.88085.4934
Very volatile
Receivables Turnover3.423.604313.3245
Pretty Stable
Graham Number0.150.16081.268
Pretty Stable
Shareholders Equity Per Share0.01260.01320.2986
Pretty Stable
Debt To Equity0.330.320.2978
Pretty Stable
Capex Per Share2.0E-42.0E-40.0045
Pretty Stable
Average Receivables816.7 K1.2 M1.1 M
Slightly volatile
Revenue Per Share0.05360.05540.0934
Pretty Stable
Interest Debt Per Share0.00480.0050.0407
Pretty Stable
Debt To Assets0.09830.09360.0846
Pretty Stable
Operating Cycle115121396
Pretty Stable
Price Book Value Ratio5.565.85091.8 K
Slightly volatile
Days Of Payables Outstanding278142394
Slightly volatile
Ebt Per Ebit1.931.83831.0985
Slightly volatile
Company Equity Multiplier3.553.37981.7132
Slightly volatile
Long Term Debt To Capitalization0.00320.00330.1199
Slightly volatile
Total Debt To Capitalization0.250.230.1627
Very volatile
Debt Equity Ratio0.330.320.2978
Pretty Stable
Quick Ratio0.790.83165.1999
Very volatile
Net Income Per E B T0.80.890.967
Slightly volatile
Cash Ratio0.230.24334.6756
Very volatile
Days Of Inventory Outstanding19.0420.041192.788
Pretty Stable
Days Of Sales Outstanding154101297
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.121.00341.0254
Slightly volatile
Price To Book Ratio5.565.85091.8 K
Slightly volatile
Fixed Asset Turnover30.4328.97949.5986
Slightly volatile
Debt Ratio0.09830.09360.0846
Pretty Stable
Price Sales Ratio1.331.39723.5 K
Slightly volatile
Asset Turnover1.31.23890.4059
Slightly volatile
Price Fair Value5.565.85091.8 K
Slightly volatile

Genetic Technologies Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap10.2 M10.7 M1.5 B
Slightly volatile
Enterprise Value10 M10.6 M1.5 B
Slightly volatile

Genetic Fundamental Market Drivers

Cash And Short Term Investments1 M

Genetic Upcoming Events

29th of August 2023
Upcoming Quarterly Report
View
30th of June 2023
Next Fiscal Quarter End
View

About Genetic Technologies Financial Statements

Genetic Technologies stakeholders use historical fundamental indicators, such as Genetic Technologies' revenue or net income, to determine how well the company is positioned to perform in the future. Although Genetic Technologies investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genetic Technologies' assets and liabilities are reflected in the revenues and expenses on Genetic Technologies' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genetic Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue741.6 K378.3 K
Total Revenue7.7 M5.3 M
Cost Of Revenue3.8 M3.9 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 1.33  1.27 
Research And Ddevelopement To Revenue 0.10  0.09 
Revenue Per Share 0.06  0.05 
Ebit Per Revenue(0.85)(0.90)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
When determining whether Genetic Technologies is a strong investment it is important to analyze Genetic Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Genetic Technologies' future performance. For an informed investment choice regarding Genetic Stock, refer to the following important reports:
How To Invest In Genetic
Details
Is Genetic Stock a good investment?
Details
What is Genetic Technologies' Net Worth?
Details
Largest Life Sciences Tools & Services Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Genetic Technologies Correlation against competitors.
For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.02)
Revenue Per Share
2.19
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.63)
Return On Equity
(1.85)
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY